Carlos Clark, MD
Family Medicine · Dothan, ALNPI 1063851277
Payments from drug & device makers
Across 289 payments — averaging $14.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$579
- AstraZeneca$471
- GSK$418
- AbbVie$366
- Novo Nordisk$316
- Takeda Pharmaceuticals U.S.A., Inc.$206
- plus $2K from 29 others
What the payments were for
- Food & beverage$3,98097%
- Education$1273%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 69 | $579 |
| AstraZeneca | 20 | $471 |
| GSK | 23 | $418 |
| AbbVie(2 entities) | 26 | $366 |
| Novo Nordisk | 35 | $316 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $206 |
| Nevro Corp. | 9 | $197 |
| Astellas Pharma US Inc | 10 | $184 |
| Amgen | 10 | $144 |
| Biohaven Pharmaceuticals, Inc. | 8 | $138 |
| Amarin Pharma, Inc. | 7 | $124 |
| Novartis | 8 | $115 |
| Abbott | 8 | $110 |
| Pfizer | 5 | $73 |
| Boehringer Ingelheim | 4 | $72 |
| Sanofi-aventis U.S. LLC | 3 | $70 |
| Otsuka America Pharmaceutical, Inc. | 4 | $66 |
| Medtronic | 1 | $59 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $55 |
| Dexcom, Inc. | 3 | $44 |
| Inspire Medical Systems, Inc. | 2 | $42 |
| Corcept Therapeutics | 2 | $33 |
| Bayer | 2 | $30 |
| Lilly USA, LLC | 2 | $27 |
| E.r. Squibb & Sons, L.L.C. | 2 | $22 |
| Corium, LLC | 1 | $21 |
| Phathom Pharmaceuticals, Inc. | 1 | $19 |
| Daiichi Sankyo Inc. | 1 | $16 |
| Esperion Therapeutics, Inc. | 1 | $14 |
| Merck | 1 | $13 |
| Exact Sciences | 1 | $13 |
| Avanir Pharmaceuticals, Inc. | 1 | $13 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
| Acadia Pharmaceuticals Inc | 1 | $12 |
| Shire North American Group Inc | 1 | $11 |
How this compares
$4,107 in reported general payments places this provider in the 80th percentile of 1,680 family medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 1,443 | $557,128 |
| AustedoDeutetrabenazine | 123 | $360,094 |
| FarxigaDapagliflozin Propanediol | 360 | $220,054 |
| XareltoRivaroxaban | 528 | $207,147 |
| JanuviaSitagliptin Phosphate | 416 | $196,186 |
| MounjaroTirzepatide | 143 | $155,104 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 186 | $133,668 |
| RexultiBrexpiprazole | 180 | $132,240 |
| OzempicSemaglutide | 138 | $131,600 |
| LinzessLinaclotide | 195 | $114,153 |
| TrulicityDulaglutide | 111 | $107,794 |
| IngrezzaValbenazine Tosylate | 27 | $106,346 |
| NuedextaDextromethorphan Hbr/Quinidine | 140 | $103,442 |
| JardianceEmpagliflozin | 185 | $84,428 |
| EntrestoSacubitril/Valsartan | 165 | $75,794 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $73 | $557,1281,443 claims |
| Johnson & JohnsonXarelto, Invega Sustenna | $579 | $281,344554 claims |
| Lilly USA, LLCMounjaro, Trulicity | $27 | $262,898254 claims |
| AstraZenecaFarxiga, Brilinta | $471 | $245,628448 claims |
| MerckJanuvia, Janumet | $13 | $243,658455 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arexvy, Anoro Ellipta | $418 | $236,161414 claims |
| Novo NordiskOzempic, Rybelsus, Levemir | $316 | $200,286328 claims |
| AbbVieLinzess, Rinvoq | $366 | $188,906206 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $66 | $132,240180 claims |
| Boehringer IngelheimJardiance, Tradjenta | $72 | $108,376243 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $13 | $103,442140 claims |
| NovartisEntresto | $115 | $75,794165 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,680 family medicine providers in Alabama.
Other family medicine in Dothan
- Philip WilsonDothan$50K
- Michael VaughnBirmingham$9.9M
- William NixonGuntersville$7.1M
- Randall QuinnCullman$5.4M
- Matthew CaldwellAthens$4.1M
- Michael CarterHuntsville$3.4M
- Howard RubensteinSaraland$3.3M
- Randle MiddletonHuntsville$3.3M
- Aaron KarrSheffield$3.1M
- Nidal MorrarFoley$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.